Teva Pharmaceuticals gained FDA approval to launch the first generic GLP-1 drug for weight loss, a liraglutide injection based on Saxenda.

President Trump urged pharmaceutical companies to publicly prove that their Covid-19 products work, saying in a Truth Social ...

Israeli drugmaker Teva Pharmaceutical Industries has announced US Food and Drug Administration (FDA) approval and launch of a generic version of Saxenda (liraglutide injection).

Although Saxenda is the first generic GLP-1 to hit the US market, its sales will likely be overshadowed by next-gen drugs ...

In December 2024, Teva also secured FDA approval for the other liraglutide brand Victoza, indicated for type 2 diabetes.

In separate announcements, Form Health and 9amHealth said they would provide patients seeking support for obesity care with ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug market, revolutionizing diabetes and obesity treatment with its ...

Novo Nordisk (NVO), the Danish pharmaceutical leader, has reclaimed its dominance in the GLP-1 market, driven by strategic agility and innovative breakthroughs.

GoodRx and Novo Nordisk partnered to make Ozempic and Wegovy available at $499 per month at more than 70,000 pharmacies nationwide. BioMed X and Novo launched a collaboration in oral peptide drug ...

Health Ozempic Maker Novo Nordisk Freezes Hiring Amid Ongoing Struggles The Danish pharmaceutical company has struggled in recent months to meet its lofty sales expectations.

Medicare drug plans don’t cover Saxenda because Medicare doesn’t cover GLP-1 agonists when prescribed for weight loss.

Medicare drug plans don’t cover Saxenda because Medicare doesn’t cover GLP-1 agonists when prescribed for weight loss.